The clinical chemistry test is intended to help diagnose heart failure using the N-terminal pro b-type natriuretic peptide biomarker.

Last week, readers were most interested in a story about Roche gaining FDA clearance and CLIA waiver for its STI point-of-care test.

The finalized local coverage determinations were set to go into effect on Feb. 23 but have been pushed back two months.

OraSure Technologies CEO Carrie Eglinton Manner said in her presentation that the firm's recent $25 million acquisition of ...

The molecular test is used to differentiate bacterial infections, viral infections, and noninfectious disease and to assess ...

The QuickFinder COVID-19/Flu Antigen Self-Test and the QuickFinder COVID-19/Flu Antigen Pro Test detect SARS-CoV-2, influenza A, and influenza B in swab specimens and provide results within 15 minutes ...

Laboratory Corporation of America has launched its MS Monitoring Profile test, which combines the measurement in blood of the biomarkers neurofilament light chain and glial fibrillary acidic protein ...

The organization is leveraging its growing bank of whole-slide pathology images to create models that could form the backbone of cancer testing applications.

Highlights from the first day included updates from several firms about their China businesses and M&A strategies.

Highlights from the third day included information about Quanterix's new Simoa One platform, expected to launch at the end of ...

Roche plans to release the system in the US to run tests including vitamin D and steroid assays under CLIA before it possibly receives US Food and Drug Administration clearance.